UPB Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -56.03%, SMA50 -68.31%, SMA200 -58.8%). The stock’s 14-day RSI is 19.04 (weak momentum), while the ATR of 1.95 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -76.54% below its high and over 53.7% above its low. Average 10-day trading volume of 961.04 thousand shares is below the 3-month average of 1.26 million, indicating normal recent market interest.

Upstream Bio, Inc. has 53.91 million shares outstanding. The public float is 31.42 million shares, elevated short interest at 10.38% of float. This equals 3.10 million shares. The short ratio is 6.78 days. Institutional investors hold 102.82% of the float. Insiders own 14.77%. Sutherland Everett Rand holds 72.91 thousand shares, Deykin Aaron has 32.69 thousand shares and GRAY MICHAEL has 29.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.01 thousand shares across 5 transactions.

Wall Street analysts project EPS growth of 14.52% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $51.00 to $40.00. The high target offers 488.91% upside. The low target suggests 361.89% downside. The mean target is $45.25. This offers 422.52% upside. Upstream Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -19.23%. The prior quarter beat by 21.31%. Over the last six quarters, Apple has recorded several small beats. These include 1200.3% in November 07, 2024.

Upstream Bio, Inc. (NASDAQ:UPB) closed at $8.66 USD, losing -$1.05 (-10.76%) from the previous close of $9.71. The stock is currently mid-range between its 52-week high and low $5.14 and $33.68. With a market capitalization of about $468.24 million, Upstream Bio, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.99). Key stats such as the average daily volume over the past year has been around 1.27 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Upstream Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO E. Rand Sutherland, the company employs approximately 52 people and listed since October 11, 2024. Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.

Upstream Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.00. This means the shares are trading above this model’s fair value.

Upstream Bio, Inc. trades at a P/E ratio of -3.84, slightly below the S&P 500 average, with a price-to-sales ratio of 167.87 and a price-to-book ratio of 1.24 suggesting the stock is closer to book value. The P/FCF stands at -3.84, also below market averages.

Upstream Bio, Inc. (NASDAQ:UPB) shares are up 14.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Upstream Bio, Inc. trading at a premium to the broader market with a P/E of -3.84. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $45.25, suggesting 422.52% upside. Our AI forecast model points to short-term weakness (-89.61% over two weeks), a medium-term rise (159.35% over three months), and a longer-term gain (179.45% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Upstream Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -89.61%, with price expected at $0.90 by March 31, 2026, within a range of $0.00 to $6.96 3-Month Outlook: Projected rise of 159.35%, reaching $22.46 by June 15, 2026, with a range of $21.87 to $23.03. 1-Year Outlook: Projected gain of 179.45%, with price at $24.20 by March 17, 2027, within a range of $23.78 to $24.64.